Business Wire

WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future

23.6.2026 12:00:00 CEST | Business Wire | Press release

Share

Philip Morris International and WSJ Intelligence reveal a "Human Premium" in the AI era, warning of cognitive atrophy risks alongside rapid corporate automation

Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today revealed topline findings from a forthcoming study at Journal House during the Cannes Lions International Festival of Creativity. The study delivered a clear takeaway for global businesses: human cognition must be the absolute forefront of the modern corporate landscape. The findings show that uniquely human skills are vital, non-replicable, and increasingly valuable in an AI-embedded future, with creative empathy and critical thinking among the most distinctive workplace advantages.

Surveying over 2,500 business professionals across the United States, United Kingdom, Italy, South Africa and Brazil, the joint initiative is the largest-scale research program ever conducted by WSJ Intelligence. The full survey results will be released in September in a deep-dive report on the growing value of human cognition.

At PMI, we believe that as AI becomes more embedded in businesses, leaders have a responsibility to ensure it strengthens - not weakens - the human capabilities that drive sound judgment, creativity, empathy, and responsible decision-making,” said Moira Gilchrist, Chief Global Communications Officer. “This research reinforces our view that human cognition is a strategic resource, and one that companies must protect and develop as they shape the future of work.”

As organizations scale up integration of AI, the study highlights a profound operational shift. Rather than focusing merely on job replacement, the research introduces the concept of the “Human Premium” - the indispensable value of human intuition, ethical judgment, and critical thinking. The multi-tier insights track alignment and divides across entire organizational structures, mapping sentiments from entry-level associates up to the C-suite.

The report identified six key findings:

  • The Trust Deficit: While AI tool integration is scaling, a trust gap remains between heavy tool usage and actual reliance on unreviewed outputs. For example, 83% of respondents use AI for research and information synthesis weekly, but only 57% have a complete or high level of trust in its output.
  • Human Intuition Wins: When AI and human insights conflict, 62% of global professionals state human intuition must remain the final authority for creative and strategic decisions.
  • Cognitive Atrophy Risks: Critical thinking is ranked as the most vital asset in the modern workplace, but professionals feel it is also the attribute at the highest risk of being eroded by overreliance on AI.
  • Human Skills Rising in Importance: Over the next three years, the human skills projected to experience the highest growth in corporate importance are creative empathy and adaptability.
  • The Seniority Divide: C-Suite executives are twice as likely as entry-level staff to report advanced AI proficiency (33% vs. 15% expert/advanced proficiency, respectively) and to trust its outputs.
  • The Efficiency Reinvestment: AI has the potential to act as a catalyst for quality. 7 in 10 professionals are taking the time freed up by automation and deliberately reinvesting it into high-value, strategic work.

To contextualize these findings for global enterprises, WSJ’s custom content studio, The Trust, will be releasing a Custom Research Report later this year that delves deeply into the preservation of workforce cognition, mapping the mandates required to keep human cognition prioritized in future workplace ecosystems. PMI and The Trust are also partnering on a four-episode vodcast series where each episode is grounded in a core study insight, introducing prominent psychologists, neuroscientists and industry leaders to analyze what these technological shifts mean for human cognition under real-world business challenges.

To preview the study’s findings and put your own cognition to the test, PMI and The Trust developed Reality Check, a cognitive test designed to assess how you process, evaluate and make decisions under pressure in an AI-driven world.

Earlier this year, as global leaders from the worlds of business, politics, and policy convened in Davos, PMI called for global dialogue following the release of its white paper, Human Cognition: The Next Frontier?, which argues that cognition should be treated as a scarce and strategic resource as AI automates routine knowledge work.

Methodology

This study, conducted by WSJ Intelligence with sponsorship from PMI, presents the key findings of a survey of 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil.

Philip Morris International: A Global Smoke-Free Champion

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch, and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 43% of PMI’s first-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumablesand General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

About WSJ Intelligence

WSJ Intelligence conducts best-in-class bespoke research and analysis for commercial clients of The Wall Street Journal, Barron’s, MarketWatch, Mansion Global and Investor’s Business Daily. Using various qualitative and quantitative methodologies and rigorous analysis, WSJ Intelligence collaborates with clients to create compelling and clear executive-level narratives and uses our world-class brands as distribution channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260623366308/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release

A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel

China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release

The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,

Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release

Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye